STOCK TITAN

Tscan Therapeutics Inc - TCRX STOCK NEWS

Welcome to our dedicated news page for Tscan Therapeutics (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tscan Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tscan Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.83%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.21%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.3%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
none
Tscan Therapeutics Inc

Nasdaq:TCRX

TCRX Rankings

TCRX Stock Data

371.26M
21.10M
0.89%
83.08%
0.46%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Waltham

About TCRX

harnessing novel t cell systems to extend the promise of immunotherapy